Back
| Semester | spring semester 2015 |
| Course frequency | Every spring sem. |
| Lecturers |
Heinz Läubli (heinz.laeubli@unibas.ch)
Philipp Müller (ph.mueller@unibas.ch, Assessor) |
| Content | The aim of the course is to give students in the life science area a broad overview as well as knowledge in the area of cancer research. The lecturers discuss all aspects of cancer research, ranging from the diagnosis and pathology of cancer to molecular aspects of applied and basic cancer research. The lecture will cover new classes of cancer therapeutics with a particular focus on immuno-therapies and antibody-drug-conjugates. It will further discuss synergies between 'old' as well as 'new' anti-cancer drugs, such as targeted agents and chemotherapeutics, and novel immuno-therapies. Finally it will provide insight into on going clinical as well as basic cancer research and present findings from the lecturers own research. 18.02.2014 1) Introduction, overview and horizon of expectation; Ø Dr. Heinz Läubli (Arzt Onkologie) Pathology and its role within oncological diagnostics and decision-making (e.g. selection of the most effective therapy) (perspective on lecture 2) Ø Dr. Spasenija Savic (Oberärztin Pathologie) 25.02.2014 Fasnachtswoche (Vorlesungsfrei) 04.03.2014 2) Insight into the oncological practice (In reference to lecture 1) Ø Dr. Marcus Vetter (Oberarzt Onkologie) 11.03.2014 3) “Targeted Agents” within the oncological practice; translational aspects and insight into own research. Ø Dr. Sacha Rothschild (Oberarzt Onkologie) 18.03.2014 4) Cancer Immunotherapy, latest developments, novel therapeutics to come; insight into own research Ø Dr. Heinz Läubli (Arzt Onkologie) 25.03.2014 5) Antibody-Drug Conjugates with a focus on microtubule targeting agents (e.g. Brentuximab Vedotin and T-DM1); Insight into own research, synergies with immunotherapy. Ø Dr. Philipp Müller (Stv. Laborleiter; Projektleiter; Cancer Immunotherapy) 01.04.2014 6) Tumor-angiogenesis, metastasis, epithelial–mesenchymal transition (EMT) and anti-angiogenic therapy; insight into own research Ø Dr. Andreas Wicki (Oberarzt Onkologie) 08.04.2014 EXAM |
| Learning objectives | 1) Insight into the oncological practice 2) Pathology and its role within oncological diagnostics and decision-making (e.g. selection of the most effective therapy). 3) 'Targeted Agents' within the oncological practice; translational aspects 4) Tumor-angiogenesis, metastasis, epithelial–mesenchymal transition (EMT) and anti-angiogenic therapy 5) Cancer Immunotherapy, latest developments, novel therapeutics to come 6) Antibody-Drug Conjugates with a focus on microtubule targeting agents (e.g. Brentuximab Vedotin and T-DM1); Synergies with immunotherapy 7) Therapeutic synergies of targeted agents and anti-angiogenic therapies with novel immune-based treatment approaches |
| Weblink | ADAM |
| Language of instruction | English |
| Use of digital media | No specific media used |
| Interval | Weekday | Time | Room |
|---|
No dates available. Please contact the lecturer.
| Modules |
Electives Master Molecular Biology (Master Molecular Biology) Module Specialisation: Pharmacology (Master Pharmaceutical Sciences) Module Specialisation: Toxicology (Master Pharmaceutical Sciences) |
| Assessment format | continuous assessment |
| Assessment details | Written Exam (pass/fail) http://pharma.unibas.ch/teaching/leistungsueberpruefungen/lluep/ |
| Assessment registration/deregistration | Reg.: course registration; dereg.: teaching staff |
| Repeat examination | no repeat examination |
| Scale | Pass / Fail |
| Repeated registration | as often as necessary |
| Responsible faculty | Faculty of Science, studiendekanat-philnat@unibas.ch |
| Offered by | Departement Pharmazeutische Wissenschaften |